Global Alzheimer’s Initiative Now Act
- house
- senate
- president
Last progress June 3, 2025 (6 months ago)
Introduced on June 3, 2025 by Ami Bera
House Votes
Referred to the House Committee on Foreign Affairs.
Senate Votes
Presidential Signature
AI Summary
This bill lets the United States join and help fund the Davos Alzheimer’s Collaborative, a global partnership to speed up better tests, treatments, and care for Alzheimer’s and dementia. It sets a U.S. policy to lead global efforts, including work in low- and middle-income countries where most new cases are expected, and to develop diagnostics and treatments that work for diverse populations. The bill responds to the fast-growing impact of Alzheimer’s: nearly 60 million people worldwide today, projected to more than 150 million by 2050, with costs now over $1.3 trillion a year and doubling every decade. In the U.S., cases could reach 12.7 million by 2050, with nearly $1 trillion in yearly costs; women and minority communities are hit especially hard.
The U.S. would take part in the group’s leadership by naming a qualified official to its advisory council (and possibly the board) who will coordinate with USAID, the State Department, and Health and Human Services. U.S. contributions can use foreign assistance funds, but only if other donors also give; from fiscal years 2026 through 2030, the U.S. share cannot exceed one-third of the total. The Administration must report to Congress within 180 days and then every year on contributions, governance, outside funding, and how the effort supports U.S. health strategies. The Davos Alzheimer’s Collaborative aims to raise over $700 million in six years and already supports health systems in multiple countries, including the United States.
Key points
- Who is affected: People living with Alzheimer’s and dementia, their families and caregivers; especially women and minority communities that face higher impacts.
- What changes: The U.S. joins a global Alzheimer’s effort, contributes funds with a one-third cap and matching requirement, puts a U.S. representative in leadership, and aligns work across federal health and development agencies.
- When: Funding limits apply in fiscal years 2026–2030; federal reports start 180 days after the bill becomes law and continue annually.